Alpha1-proteinase inhibitor
ApprovedBiologic
CSL BehringAlpha1-proteinase inhibitor is one of 81 biologic programs targeting Emphysema. It is currently in Approved.
3
Indications
7
Total Trials
0
Active Trials
80
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
547 competitors in Pneumonia
#DrugCompanyPhaseTrials
1Alpha1-proteinase inhibitor
CSL BehringApproved
Acanya
PfizerPreclinical
Prevacid
TakedaPreclinical
Avlosulfon
AAlmirall, S.A.
Preclinical
Neutrexin
WWest Japan Thoracic Oncology Group
Preclinical
Primsol
CConrado Roberto Hoffmann Filho
Preclinical
Gantanol
CConrado Roberto Hoffmann Filho
Preclinical
Zantac 150
CChattem
Preclinical
Pepcid
KKenvue Brands
Preclinical
Mycifradin
PPharmacia and Upjohn
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Emphysema3 trials
Efficacy and Safety1 trial
Pneumonia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Alpha1-proteinase inhibitor. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Approved[1]
- Company